The University of Pittsburgh Head and Neck Cancer SPORE will establish a Histology/Tissue Banking Core to ensure efficient use of head and neck tissue specimens and provide routine and specialized histologic evaluation of these tissues for the SPORE's research projects. The goal is to provide sufficient and well-characterized tissues of the highest quality in support of research studies in this SPORE and those of collaborating SPORE institutions. Tissue specimens as well as blood and body fluid samples will be systematically collected from head and neck cancer patients or from non-cancer patients to be used as controls. The Core will be responsible for collection, triage, processing and distribution or storage of specimens and tissue histopathology, immunohistochemistry, and interpretation. Research specimens, including snap-frozen, OCT-embedded, archival or fresh tissue blocks, cells (tumor or tumor infiltrating lymphocytes) dissociated from tissues, peripheral blood mononuclear cells, and paraffin embedded or frozen tissue sections for immunohistochemical analysis and tissue microarrays, will be triaged for distribution to the investigators, as specified by the research protocol. Microdissection of tissues and extraction of DNA and/or RNA for molecular assays will also be performed. The Core will bank any samples that are not used immediately by the SPORE investigators for future use by SPORE developmental research projects and SPORE projects at collaborating institutions. Histopathologic analysis by the Core Pathologists will confirm the quality of and the presence of the expected target tissue in research specimens. Immunohistochemistry will be used to detect cellular biomarkers, whose expression in target tissues may be correlated with clinical outcome. The Core will track samples and facilitate the sharing of specimens by the research laboratories according to a priority schema to be reviewed and approved by the Executive Committee of the SPORE. Specimen processing, inventory, and distribution data and histopathologic analysis results will be maintained in the Core's computerized database with links to the Bioinformatics component of the Biostatistics Core for storage and archiving to facilitate a web-based retrieval system. This database will be designed for use by all SPORE investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097190-03
Application #
7267744
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
3
Fiscal Year
2006
Total Cost
$169,309
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Gleber-Netto, Frederico O; Zhao, Mei; Trivedi, Sanchit et al. (2018) Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer 124:84-94
Santuray, Rodell T; Johnson, Daniel E; Grandis, Jennifer R (2018) New Therapies in Head and Neck Cancer. Trends Cancer 4:385-396
Liu, Zhuqing; McMichael, Elizabeth L; Shayan, Gulidanna et al. (2018) Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. Clin Cancer Res 24:4529-4538
Lu, Shanhong; Concha-Benavente, Fernando; Shayan, Gulidanna et al. (2018) STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV+ status in head and neck cancer. Oral Oncol 78:186-193
Nikiforova, Marina N; Mercurio, Stephanie; Wald, Abigail I et al. (2018) Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. Cancer 124:1682-1690
Zhong, Qian; Liu, Zhi-Hua; Lin, Zhi-Rui et al. (2018) The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. Clin Cancer Res 24:659-673
Ma, Jing; Salamoun, Joseph; Wipf, Peter et al. (2018) Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget 9:6042-6054
Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287
Pai, Sara I; Jack Lee, J; Carey, Thomas E et al. (2018) HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. Oral Oncol 77:92-97
Shayan, Gulidanna; Kansy, Benjamin A; Gibson, Sandra P et al. (2018) Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. Clin Cancer Res 24:62-72

Showing the most recent 10 out of 310 publications